A$3.06 pre-market: Artrya (AYA.AX) ASX 19 Mar 2026 AI stock outlook

AYA.AX stock opened pre-market at A$3.06 on 19 Mar 2026 as investors assess Artrya Limited’s AI diagnostic traction in coronary disease. Artrya (AYA.AX) trades on the ASX and has a market capitalisation of A$350,504,000 while trading between A$3.04 and A$3.15 intraday. The company’s cloud AI product Salix targets automated coronary CT angiography reads, and recent trading reflects mixed sentiment between robust cash per share and negative earnings. We examine fundamentals, technicals, Meyka AI grades and model forecasts to outline near-term scenarios for this AI healthcare stock.

AYA.AX stock: Key facts and market snapshot

Artrya (AYA.AX) is trading at A$3.06 on the ASX with a market cap of A$350,504,000.

Volume is 132,191 versus an average daily volume of 548,028, and the stock opened at A$3.15 with a previous close of A$3.12.

AYA.AX stock: Fundamentals and valuation

AYA.AX reports EPS of -0.17 and a trailing PE of -18.12, signalling current losses.

The company holds A$0.61 cash per share and book value per share of A$0.71, producing a price-to-book of 4.33, slightly above the Healthcare sector average PB of 4.11. Revenue per share is immaterial at 0.00, and R&D intensity is high at 84.34% of revenue, reflecting early-stage commercial investment.

AYA.AX stock: Technicals, momentum and liquidity

Short-term momentum is neutral with RSI at 43.76 and MACD at -0.09 (signal -0.11).

Price sits near the middle Bollinger band (BB mid 3.21), ATR is 0.26, and relative volume is 0.24, indicating lighter trading today compared with recent average activity.

AYA.AX stock: Growth outlook and Meyka AI forecasts

Meyka AI’s forecast model projects a monthly price of A$3.05, a quarterly target of A$4.36, and a yearly projection of A$7.41. These imply short-term flat performance of -0.33% for one month, +42.48% to the quarter, and +142.04% to one year compared with the current A$3.06.

Forecasts are model-based projections and not guarantees. The medium-term upside reflects accelerating commercial adoption assumptions for Salix across radiology networks and recurring cloud revenue growth.

AYA.AX stock: Risks and opportunities

A clear opportunity is Artrya’s AI product Salix addressing an unmet clinical workflow need, which could scale recurring revenue if regulatory and hospital integrations proceed.

Key risks include ongoing negative margins (net income per share -0.16), high valuation ratios versus near-term revenue, and thin trading liquidity relative to large-cap peers which can magnify price swings.

Meyka grade, analyst signals and price targets

Meyka AI rates AYA.AX with a score of 63.42/100, Grade B, Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Independent company analytics note a company rating of C (Sell) dated 17 Mar 2026. Model-based near-term price targets: A$4.36 (3 months) and A$7.41 (12 months). Investors should treat these as scenario targets, not guarantees.

Final Thoughts

Artrya (AYA.AX) trades pre-market at A$3.06 on the ASX as the market balances AI-driven growth potential against current losses. Fundamental strength includes A$0.61 cash per share and a low debt profile, while valuation metrics such as PB 4.33 and negative PE reflect a company still scaling revenue. Technically the stock is neutral with RSI 43.76 and below-average volume today. Meyka AI’s forecast model projects A$4.36 at three months and A$7.41 at one year, implying upside of +42.48% and +142.04% respectively from A$3.06. Meyka AI rates AYA.AX 63.42/100 (Grade B, HOLD), combining sector and growth factors. For investors focused on AI healthcare exposure, AYA.AX stock offers high-reward potential tied to commercial execution and regulatory progress, but carries elevated volatility and near-term earnings risk. Monitor upcoming milestones, volume trends, and the company earnings announcement on 27 Aug 2026 for clearer catalysts. Model forecasts are projections and not guarantees, and this analysis is informational, not financial advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.